

Cancer Risk Prediction Models Workshop

Current Population Resources for the Development and Validation of Cancer Risk and Susceptibility Prediction Models

Daniela Seminara, PhD, MPH

Epidemiology and Genetics Research Program



Role of Extramural NCI

- Assessing needs
- Providing resources (NCI Bypass budget 2005)
- Facilitating and expediting research implementation and translational process
- Coordinating availability and knowledge dissemination

Cancer Risk Prediction and Susceptibility Models: Goals (I)

1. Extension/refinement of models currently in use to better define at-risk populations by incorporating data on
 - multiple genes
 - low penetrance polymorphisms
 - precursor lesions (i.e. polyps, DCIS)
 - genetic/bio markers (i.e. MSI)
 - pathology information (i.e. ER)
 - treatment/preventive intervention

Cancer Risk Prediction and Susceptibility Models: Goals (II)

2. Development of new models

- more precise/accurate models for common cancers
- “de novo” models for rare cancers or familial syndromes

3. Validation of existing models

- Compare prediction of same model in different populations
- Compare predictions from various models in the same data set

4. Applications

- Benefit to patients
- Rapid dissemination of new knowledge to clinicians, scientists and policy makers

Some Limitations of Current Data Sets

- Limited data on racial/ethnic groups
- Lack of prospective data on environmental risk factor
- Missing data on risk factors
- Incomplete genetic profile
- Accuracy of FH
- Sensitivity of mutation detection methods

Research Projects Supported

➤ DCCPS

▶▶ 872 active grants

▶▶ \$374,000,000


❖ EGRP

❖ 410 active projects

❖ \$199,000,000

EGRP- Supported Epidemiology Consortia

Gene discovery
Gene characterization
GxG and GxE



Translational Clinical
Genetics
Screening/prevention
/treatment

Research Infrastructures Hybrid Design

➤ The Breast and Colon Cancer Family Registries*

<http://epi.grants.cancer.gov/CFR/>

Contact: Daniela Seminara, seminard@mail.nih.gov

➤ The Cancer Genetics Network (All cancer sites)**

<http://epi.grants.cancer.gov/CGN/>

Contact: Carol Kasten-Sportes, kastenca@mail.nih.gov

*Family, case-control and hybrid designs

** Screening, clinical trials

Case-Control Consortia

- Interlymph (lymphomas)
- Molecular Epidemiology of Colorectal Cancer (MECC)
- International Lung Cancer Consortium ★
- Head and Neck Cancer Consortium ★
- International Melanoma Consortium (case-control component)
- Brain Tumors Consortium ★
- Genetic Epidemiology of Melanoma (GEM)
- Breast Cancer, Radiation Exposure and Cancer Susceptibility Genes (WE CARE)

★ Newly formed

Information: <http://epi.grants.cancer.gov/Consortia/casecontrol.html>

Familial Consortia (Clinics)

- Genetic Epidemiology of Lung Cancer (GELC)
- International Melanoma Consortium (familial component)
- International Consortium on Prostate Cancer Genetics (ICPCG)
- Pancreatic Cancer Genetic Epidemiology Network (PACGEN)
- Chronic Lymphocytic Leukemia Familial Consortium
- Multiple Myeloma Familial Consortium ★
- Lymphoproliferative Cancers Familial Consortium ★

★ Newly formed

Contact: Daniela Seminara, seminard@mail.nih.gov

Large Cohorts Supported by EGRP (I)

Black Women's Cohort: A Follow-up Study for Causes of Illness in Black Women

Lynn Rosenberg, Sc.D., Boston University

Breast Cancer Prognostic Factors/Pathobiology

Kathleen Malone, Ph.D.

Fred Hutchinson Cancer Research Center

California Teachers Study: Breast and Other Cancers in the California Teachers' Cohort

Ronald Ross, M.D., University of Southern California/Norris Comprehensive Cancer Center

Cancer in American Natives: A Prospective Study of Alaska Natives and American Indians

Martha Slattery, Ph.D., University of Utah

Anne Lanier, M.D., M.P.H., Alaska Native Tribal Health Consortium

Jeffrey Henderson, M.D., M.P.H., Black Hills Center for American Indian Health

Health Professionals Follow-up Study: Prospective Studies of Diet and Cancer in Men and Women

Walter Willett, M.D., M.P.H., Dr.P.H., Harvard School of Public Health

Iowa Women's Health Study: Epidemiology of Cancer in a Cohort of Older Women

Aaron Folsom, M.D., M.P.H., University of Minnesota

Multiethnic/Minority

Laurence Kolonel, M.D., Ph.D., Cancer Research Center of Hawaii

Large Cohorts Supported by EGRP (II)

Nurses' Health Study I

Graham Colditz, Dr.P.H., M.D., Harvard School of Medicine

Nurses' Health Study II

Walter Willett, M.D.,M.P.H., Dr.P.H., Harvard School of Public Health

Prospective Study of Breast Cancer Survivorship

Lawrence Kushi, Sc.D.
Kaiser Permanente

Seventh-day Adventist Cohort Study: Cancer Epidemiology in Adventists - A Low Risk Group

Gary Fraser, M.B.Ch.B., Ph.D., M.P.H., Loma Linda University

Singapore Cohort Study of Diet and Cancer

Mimi Yu, Ph.D., University of Southern California/Norris Comprehensive Cancer Center

Southern Community Cohort Study

William Blot, Ph.D., Vanderbilt University and International Epidemiology Institute, Ltd.

VITAL Vitamins and Lifestyle Study: Cohort Study of Dietary Supplements and Cancer Risk

Emily White, Ph.D., Fred Hutchinson Cancer Research Center

Current EGRP-Supported Cohort Studies

<http://epi.grants.cancer.gov/ResPort/cohorts.html>

Contact: Sandra Melnick, melnicks@mail.nih.gov

Consortium of Cohorts (Co-Co)

<http://epi.grants.cancer.gov/Consortia/cohort.html>

Contact: Edward Trapido trapidoe@mail.nih.gov

or, for list of P.I.s,

http://ospahome.nci.nih.gov/cohort/rosters/nov01_roster.html

Table of Cohorts Characteristics (Co-Co)

<http://ospahome.nci.nih.gov/cohort/table.htm>

Surveys

National Health and Nutrition Examination
Surveys - CDC (NHANES)

<http://archive.nlm.nih.gov/proj/dxpnet/nhanes/nhanes.php>

Behavioral Risk Factors Surveillance System -
CDC (BRFSS)

<http://www.cdc.gov/brfss/about.htm>

Physicians' Health Survey – ARP, DCCPS

<http://cebp.aacrjournals.org/cgi/content/full/12/4/295#SEC2>

Intervention trials supported by NCI: www.cancer.gov

The Cohort Consortium

The Cohort Consortium was formed by NCI to address the need for large-scale collaborations for study of gene-gene and gene-environment interactions in the etiology of cancer, and more than 20 cohorts are participating.

Cohort Consortium Membership

Invited: general cohort studies worldwide with >10,000 subjects, blood samples (including white blood cells) and questionnaire data on important cancer risk factors.

Cohorts Assembled for Co-Co 1

Study	Year started	Subjects with blood samples	Breast cancer cases	Prostate cancer cases
EPIC	1992	397,256	2,050	900
ACS (CPS-II)	1998	39,000	500	1,450
ATBC	1991	20,500	-	1,180
HARVARD:				
Phys. HS I-II	1982	20,000	-	1,500
Nurses HS	1989	32,826	945	-
HealthProfS	1993	33,240	-	600
WomenH	1993	28,263	675	-
MultiEthnicC	1983	100,000	1,990	2,400
PLCO	1993	75,000	-	1,000
Total		797,085	6,160	9,030

Proof of Principle Study

▶ Goals

- ▶ To define disease-related haplotypes by resequencing DNA from known breast and prostate cancer cases, thereby oversampling for rare mutations;
- ▶ To assess relations with plasma steroid hormone and IGF levels; and
- ▶ To examine interactions with known lifestyle and environmental factors.

Proof of Principle Study

- ▶ **Candidate genes were selected because of their role in disease-related pathways.**
 - ▶▶ **They include androgens, estrogens, gonadotropins, steroid synthesis, IGF, growth hormones, and some binding proteins. NIEHS is sponsoring additional resequencing of environmentally responsive genes, and NHLBI is sponsoring resequencing of inflammatory genes.**
- ▶ **Initial targets are 53 genes suspected of having associations with one or both cancers.**
 - ▶▶ **Work is near completion**
 - ▶▶ **Genetic data will be made public**

Project Flowchart

Selection of candidate genes
(53 genes involved in metabolism of IGF-I and steroid hormones)

SNP discovery by gene resequencing

Haplotype tagging

Genotyping

Hormone measurement

Statistical analysis
(main effects of SNPs and haplotypes,
gene-environment interactions)

Breast, Ovarian and Colorectal Cancer Family Registries (CFRs)


Goals

Ascertain, characterize and follow up a familial cohort spanning the whole spectrum of cancer risk, and establish a comprehensive familial infrastructure for the implementation of collaborative, interdisciplinary research protocols in the genetic epidemiology of cancer

Identify subpopulations at higher cancer risk that could benefit from enrollment in preventive and therapeutic interventions

Contribute to the development of effective Public Health measures by increasing knowledge of the genetic factors affecting cancer susceptibility and their interaction with modifiable environmental and lifestyle factors (general population).

CFRs: Participating Sites



BC-CFRs Design

Participating Sites

Informatics Center

Biospecimen Repositories

Population Based and Clinic-based Ascertainment

DATA

Family History

Risk Factors Qs

Medical/Pathology

Biospecimen Tracking

Follow-up

Molecular Characterization

Pilot Studies

F
I
R
E

W
A
L
L

Central Registry Data Base

Methodologic Development

- Communication
- Coordination
- Information

REGISTRY DATA

C
O
L
L
A
B
O
R
I
A
T
I
V
E

Molecular Genetics Laboratories

Designs for Studying Association in the CFRs


D. Thomas, in preparation

- ▶ **Population-based case-control studies**
- ▶ **Family-based designs:**
 - ▶ **Case-parent triads**
 - ▶ **Discordant sibships**
 - ▶ **Kin-cohort designs**
 - ▶ **Case-control family designs**
 - ▶ **High-risk family designs**


Breast CFR Enrolled Probands, Relatives, and Population Controls

Controls Probands Relatives (1st degree)


Population-
Based
Controls



Clinic-
Based
Probands/
Relatives



Population
-Based
Probands/
Relatives



Ascertainment

Population-Based Probands	49%
Clinic-Based Probands	26%
Population-Based Controls	25%

August 2003

0 5,000 10,000 15,000 20,000 25,000

Breast CFR Probands with Early and Intermediate Age at Onset

Clinic-
based
Probands



Population
based
Probands




< 36 Years of Age
36-49 Years of Age

August 2003

0 500 1,000 1,500 2,000 2,500 3,000 3,500

Breast CFR BRCA1/2 Mutational Analysis




August 2003


Colon CFR Accrued Probands, Relatives, and Controls

Controls Probands Relatives (1st degree)


Population-
Based
Controls



Clinic-
Based
Probands/
Relatives



Population
-Based
Probands/
Relatives




Ascertainment	
Population-Based Probands	59%
Clinic-Based Probands	7%
Population-Based Controls	34%

August 2003


0 5,000 10,000 15,000 20,000 25,000



Colon CFR Age at Onset of Probands



Colon CFR MSI and IHC Analysis



August 2003



Access to Collaborative Research

- **Proposal for collaborative protocols are strongly encouraged from national and international groups with appropriate expertise.**
- **Access requires formal application. Information at <http://www.cfr.epi.uci.edu/>**
- **CFRs tools and protocols are available**

“The “PERFECT” population resource/dataset does not exist...”

But we can strive to support desirable and feasible elements:

- LARGE datasets (consortia) from well ascertained caucasian and non-caucasian populations, from diverse geographical areas
 - Accurately and prospectively assessed risk factors
 - Ever improving genetic profile (biospecimen availability, technology integration)
 - Pathology, biomarkers data
 - Data on preventive interventions, treatment
- And....improved methodology to compensate for opportunistic design (often current reality)

Future Challenges/Goals for Cancer Risk Prediction

- Direct observation of impact of many interacting factors on risk
- Rapid and seamless translation of genetic epidemiology research data into model construction
- Efficient and effective translation of risk prediction models into clinical practice

Thank You

- ▶ **Sandra Melnick**
- ▶ **Ed Trapido**
- ▶ **Debbie Winn**
- ▶ **Andrew Freedman**